316 results on '"Sahai V"'
Search Results
2. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
3. Monotreme Tactile Mechanisms: From Sensory Nerves to Cerebral Cortex
4. Strategies for High-Density Cultivation of Bio-inoculants in Submerged Culture with Special Reference to Pseudomonads
5. 76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
6. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
7. LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
8. O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
9. Prebleaching of Kraft Pulps with Xylanase Enzyme for Paper Manufacture
10. Shelf-life enhancement of bio-inoculant formulation by optimizing the trace metals ions in the culture medium for production of DAPG using fluorescent pseudomonad R62
11. Evaluation of biomass
12. Determination of Age in the Living by Fusion of Manubrium Sternum and Xiphoid Process – a Radiological Study
13. P-70 First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
14. SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response
15. P-176 A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)
16. Geographic Variation in Racial Disparities in Mortality From Influenza and Pneumonia in the United States in the Pre-Coronavirus Disease 2019 Era
17. 1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC
18. Antimicrobial resistance in the Pacific Island countries and territories
19. Bench-scale fermentation of Trichoderma viride on wastewater sludge: Rheology, lytic enzymes and biocontrol activity
20. Compactin—a review
21. A chemically-defined medium for production of compactin by Penicillium citrinum
22. Application of inorganic carrier-based formulations of fluorescent pseudomonads and Piriformospora indica on tomato plants and evaluation of their efficacy
23. 326 (PB106) - Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
24. Optimal control strategy for the enhanced production of cellulase enzyme using the new mutant Trichoderma reesei E-12
25. Statistical medium optimization and production of a hyperthermostable lipase from Burkholderia cepacia in a bioreactor
26. Evaluation of biomass
27. FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
28. Optimization of compactin production in chemically defined production medium by Penicillium citrinum using statistical methods
29. Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer
30. Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
31. Predictors of Immunotherapy-Induced Immune-Related Adverse Events
32. HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA)
33. Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results
34. Development of nano-formulation containing rutin for the protective and beneficial effect against 6-hydroxydopamine induced Parkinson’s disease model via altered the genetic backgrounds
35. CHROMOSOME NUMBER OF ANTHERAEA FRITHII MOORE (LEP : SATURNIIDAE)
36. High precision droplet based new form manufacturing
37. Explanation of how to run the global local optimization code (GLO) to find surface heat flux
38. Erratum to: Quantifying the iceberg effect for injury: Using comprehensive community health data
39. Modeling of casting microstructures and defects
40. LBA40 - FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
41. 789TiP - HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA)
42. 756P - Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
43. P-155 - Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results
44. Process Optimization For Enhanced Production Of Cell Biomass And Metabolites Of Fluorescent Pseudomonad R81
45. Rajendra Sweta, a new high-yielding quality rice variety for Bihar's irrigated ecosystem
46. Rajendra Mahsuri 1, a potentially high-yielding rice variety for medium and shallow lowland ecosystems of Bihar, India
47. A Quantitative Approach to Analyze Fracture Area Loss in Shale Gas Reservoirs
48. Shakuntla: a rice variety for rainfed lowlands in Bihar, India
49. A Better Understanding of Finite Element Simulation for Shale Gas Reservoirs through a Series of Different Case Histories
50. Plant growth-promoting pseudomonad produce elicitors which induce ethylene production in host plants
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.